Press Releases
Official company announcements, financial results, and major developments from Nova Pharmaceuticals.
View Releases
Latest Press Releases
Official company announcements and press releases.
Nova Pharmaceuticals Reports Strong Q3 2024 Financial Results
Nova Pharmaceuticals today announced its financial results for the third quarter of 2024, showing continued growth in revenue and research investment. The company reported a 15% increase in revenue compared to the same period last year, driven by strong performance across all therapeutic areas.
Key Highlights:
- Revenue increased 15% year-over-year
- R&D investment up 20%
- Three new product launches
Financial Metrics:
- Q3 Revenue: $125M
- Net Income: $18M
- R&D Spend: $25M
Nova Pharmaceuticals Announces New CEO Appointment
The Board of Directors of Nova Pharmaceuticals has announced the appointment of Dr. Alexander Petrov as Chief Executive Officer, effective January 1, 2025.
Read MoreStrategic Partnership with European Pharma Company
Nova Pharmaceuticals announces strategic partnership with leading European pharmaceutical company to expand market reach.
Read MoreFDA Approval for New Cardiovascular Drug
Nova Pharmaceuticals receives FDA approval for NovaCardio Plus, expanding treatment options for hypertension patients.
Read MoreBreakthrough in Cancer Research Published
Research team publishes breakthrough findings in Nature Medicine, advancing understanding of targeted cancer therapy.
Read MoreMedia Contact
For media inquiries and press information:
media@novafarmaceuticals.com
+7 (495) 123-4571
Financial Highlights
Key financial metrics and performance indicators from our latest reports.
$125M
Q3 2024 Revenue
+15% YoY$18M
Net Income
+12% YoY$25M
R&D Investment
+20% YoY14.4%
Net Margin
+2.1% YoYMedia Inquiries
For press inquiries, interview requests, or additional information, please contact our media relations team.